Karyopharm Therapeutics Inc. recently delivered a corporate presentation highlighting their focus on the transformative opportunity in treating myelofibrosis with selinexor (XPOVIO®/NEXPOVIO®). The presentation detailed the growing global demand for selinexor, which is now approved in over 45 countries. The company anticipates a peak annual revenue opportunity of up to $1 billion in myelofibrosis. Karyopharm is conducting the Phase 3 SENTRY trial for selinexor in myelofibrosis, with top-line data expected in late 2025/early 2026. Additionally, the company continues to invest in its pipeline, including in endometrial cancer and multiple myeloma. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。